Despite being excellent proxies of AD pathology, new p-tau blood biomarkers do not present a clear bimodal distribution between non-AD and AD groups and, importantly, they present higher group-level overlaps than CSF and PET Aβ biomarkers10,38,19. The gene discussed is MAPT; the disease is Alzheimer disease.